Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 NOV 23 ... its first product for lung cancer, diagnostic assays for cervical, breast, colorectal, bladder, and oral cancers are targeted for development. Keywords: , Seniors, ...
2009 NOV 23 ... "Bacillus Calmette-Guerin is the most effective therapy for nonmuscle invasive bladder cancer. Recently to calculate the risks of recurrence and progression based on data from 7 ...
2009 NOV 24 ... concluded: "This methodology is illustrated in an application to the well-known bladder cancer study."Huang and colleagues published their study in Scandinavian Journal ...
2009 NOV 23 ... of age, race, SEER registry, gender, type of surgery (nephroureterectomy with vs without bladder cuff removal), pT stage, pN stage, grade and year of surgery. Relative to ureteral ... and 2004. Univariable and multivariable models tested the effect of tumor location on cancer specific mortality rates. Covariates consisted of age, race, SEER registry, gender, type ...
2009 NOV 23 ... conducted by the National Cancer Institute (NCI), but was discontinued due to severe bladder toxicity. The XMT-1001 program significantly improves on the clinically active drug, ...
2009 NOV 23 ... EGDE-3,3' for its potential to increase adenoviral transduction of the CAR-negative bladder cancer cell line TCCSUP. The amount of adenovirus required to transduce 50-60% of the cells was ...
2009 NOV 23 ... "Lymph node metastasis in patients who undergo radical cystectomy for bladder transitional cell carcinoma is considered a poor prognostic factor. However, patients ... Urology (Clinical Outcomes and Recurrence Predictors of Lymph Node Positive Urothelial Cancer After Cystectomy. Journal of Urology, 2009;182(5):2182-2187). Additional ...
2009 NOV 23 ... Great increase of incidence by time was found (R(2)=0.90; p=0.004). Breast, prostate and bladder cancers increase risk of second tumor in female genital organs [RR 4.78 (3.84-5.93)], ... Researchers detail in 'Multiple primary cancer: an increasing health problem. Strategies for prevention in cancer survivors,' new data ...
2009 NOV 23 ... and nongynecologic tumors of lung, esophageal, gastric, pancreatic, colonic, renal, or bladder origin. We also performed a pooled analysis of the published literature in this regard. ... frequent expression in breast and gynecologic carcinomas, the National Comprehensive Cancer Network has recommended that the immunohistochemical expression of estrogen (ER) and/or ...
2009 NOV 23 ... adenoviral vectors (AdCD40L) was used to treat an aggressive model of disseminated bladder cancer (MB49/ C57BL/6). Three weekly AdCD40L vector instillations increased overall survival of ...
2009 NOV 23 ... of differentiation. While distinct cell types have been described as important in bladder cancer in vitro, clonal and proliferative capacities of normal urothelial cells have not been ...
2009 NOV 23 ... growth factor receptor pathway profiling for prediction of lapatinib sensitivity in bladder cancer,' have been published. "Chemotherapy for metastatic...
2009 NOV 23 ... set by methylation-specific PCR in urine sediments for sensitive/specific detection of bladder cancer has been identified previously. In this study, we have evaluated 10 DNA methylation ...
2009 NOV 23 ... placed on more effective clinical approaches and biomarker assays to manage care. For bladder cancer despite the high probability of recurrence the number of patients with recurrent disease ...
2009 NOV 23 ... that cause the debilitating side effects of "fuzzy brain" (encephalopathy) and severe bladder inflammation. Intravenous palifosfamide is currently in a randomized Phase II trial, the ... of the Center for Sarcoma and Bone Oncology and the Ludwig Center at the Dana-Farber Cancer Institute and Harvard Medical School, and a member of ZIOPHARM's Medical Advisory ...
2009 NOV 23 ... that cause the debilitating side effects of "fuzzy brain" (encephalopathy) and severe bladder inflammation. Intravenous palifosfamide is currently in a randomized Phase II trial to ... seeking to develop and commercialize a diverse, risk sensitive portfolio of in-licensed cancer drugs addressing unmet medical needs, reported its financial results for the quarter ...
